Golestan University of Medical Sciences Repository

Antibody�drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes

Abdollahpour-Alitappeh, M. and Lotfinia, M. and Gharibi, T. and Mardaneh, J. and Farhadihosseinabadi, B. and Larki, P. and Faghfourian, B. and Sepehr, K.S. and Abbaszadeh-Goudarzi, K. and Abbaszadeh-Goudarzi, G. and Johari, B. and Zali, M.R. and Bagheri, N. (2019) Antibody�drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. Journal of Cellular Physiology, 234 (5). pp. 5628-5642.

Full text not available from this repository.

Abstract

Targeted delivery of therapeutic molecules into cancer cells is considered as a promising strategy to tackle cancer. Antibody�drug conjugates (ADCs), in which a monoclonal antibody (mAb) is conjugated to biologically active drugs through chemical linkers, have emerged as a promising class of anticancer treatment agents, being one of the fastest growing fields in cancer therapy. The failure of early ADCs led researchers to explore strategies to develop more effective and improved ADCs with lower levels of unconjugated mAbs and more-stable linkers between the drug and the antibody, which show improved pharmacokinetic properties, therapeutic indexes, and safety profiles. Such improvements resulted in the US Food and Drug Administration approvals of brentuximab vedotin, trastuzumab emtansine, and, more recently, inotuzumab ozogamicin. In addition, recent clinical outcomes have sparked additional interest, which leads to the dramatically increased number of ADCs in clinical development. The present review explores ADCs, their main characteristics, and new research developments, as well as discusses strategies for the selection of the most appropriate target antigens, mAbs, cytotoxic drugs, linkers, and conjugation chemistries. © 2018 Wiley Periodicals, Inc.

Item Type: Article
Additional Information: cited By 2
Uncontrolled Keywords: antibody drug conjugate; antimitotic agent; brentuximab vedotin; cytotoxic agent; inotuzumab ozogamicin; trastuzumab emtansine, bystander effect; cancer therapy; clinical outcome; cytotoxicity; drug conjugation; drug mechanism; drug selectivity; drug targeting; food and drug administration; history; human; malignant neoplasm; nonhuman; preclinical study; priority journal; Review
Subjects: آسیب شناسی QZ
Divisions: معاونت تحقیقات و فناوری
Depositing User: GOUMS
Date Deposited: 10 Apr 2019 09:28
Last Modified: 10 Apr 2019 09:28
URI: http://eprints.goums.ac.ir/id/eprint/9810

Actions (login required)

View Item View Item